Sanjay Gandhi to Quality-Adjusted Life Years
This is a "connection" page, showing publications Sanjay Gandhi has written about Quality-Adjusted Life Years.
Connection Strength
0.040
-
Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010; 13(3):428-37.
Score: 0.022
-
Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007 Dec; 106(2):229-38.
Score: 0.018